Log In
Print
BCIQ
Print
Print this Print this
 

GS-4774 (formerly GI-13020)

  Manage Alerts
Collapse Summary General Information
Company GlobeImmune Inc.
DescriptionTarmogen comprising a heat-inactivated Saccharomyces cerevisiae that expresses HBV antigens
Molecular Target HBV antigens
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat chronic HBV infection
Regulatory Designation
Partner Gilead Sciences Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today